AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05390606 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flourish HEC and BioGenesis
Description: Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
Study NCT05465395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Cervical Adjustemnt
Description: Upper cervical adjustement
Study NCT05465395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Cervical Adjustemnt
Description: Upper cervical adjustement
Study NCT05465395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Adjustemnt
Description: Thoracic adjustment
Study NCT05465395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Adjustemnt
Description: Thoracic adjustment
Study NCT06550726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
Study NCT06551896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib and immune checkpoint inhibitors
Study NCT05441982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study NCT05441982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study NCT05991934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention messages
Description: Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
Study NCT06076395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA (Laryngeal Mask Airway)
Description: Pressure controlled versus Volume controlled ventilation using LMA
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speed of Processing Training
Description: Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block.
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block.
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instrumental Activities of Daily Living Shaping
Description: In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
Study NCT05642832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Throughflow titration phase
Description: Ventilation will be applied in the TF mode with TF set to 0 LPM for 10 minutes. Patients will receive assist through the NAVA line of the tri-piece (NAVA set to similar settings as Servo period, \~60-80 LPM flow). Ventilation with Throughflow will be started at a TF flow of 5 LPM, and the NAVA flow will be reduced by 5 LPM. After 10 minutes measurements will be collected. If Edi is greater than or equal to 4 µV, TF flow will be increased to 10 LPM and NAVA flow will be adjusted to keep total flow constant. Measurements will be collected again after 10 minutes. TF flow will be increased in steps of 5 LPM and measurements collected every 10 minutes until Edi is below 3 µV or TF flow reaches the total flow observed during the NAVA period.~After either the Edi target has been met or TF flow has reached the total flow, ventilation with TF will be reduced in steps of 5 LPM every 10 minutes (the reverse of the above), while NAVA flow is accordingly adjusted to keep total flow constant.
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living Shaping
Description: In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight >= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
Study NCT04644172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
Study NCT04644172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
Study NCT06055608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
Study NCT06213987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.025% Tretinoin
Description: Total duration of 8 weeks.
Study NCT06213987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.025% Tretinoin
Description: Total duration of 8 weeks.
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Group1)
Description: Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
Study NCT06055608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Group 2)
Description: Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
Study NCT06515613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTIM-76
Description: Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.
Study NCT06144970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C High Dose
Description: High Dose - 1 mL of the combined TG-C cells
Study NCT06403657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An enhanced model of hepatitis B testing and linkage to care
Description: Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
Study NCT06144970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C Mid Dose
Description: Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
Study NCT06144970 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C Low Dose
Description: Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
Study NCT06144970 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Single subcutaneous injection of normal saline
Study NCT06654102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep UVA Irradiation
Description: A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 1 and 2 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
Study NCT06654102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep UVA+HEV Blue Light Irradiation
Description: A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 3 and 4 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
Study NCT06391424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spontaneous Breathing Trial
Description: Patients will undergo an SBT to determine whether they are ready for extubation.
Study NCT06515756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative pain assessment after root canal treatment
Description: the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
Study NCT05203068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Recombinant tuberculosis allergen (RTA)
Description: Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
Study NCT03520751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scAAV1.tMCK.NTF3
Description: gene vector
Study NCT06598436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching (Patient-Level Intervention)
Description: The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.
Study NCT06598436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (Clinic-Level Intervention)
Description: The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).
Study NCT06609525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0303-A
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study NCT06609525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0303-B
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study NCT06609525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTO0303-C
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study NCT06611007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: embolization therapy
Description: Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
Study NCT05460832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 5 mg
Description: Oral capsule
Study NCT05460832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 20 mg
Description: Oral capsule
Study NCT05460832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 40 mg
Description: Oral capsule
Study NCT05460832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT06610604 — intervention group
Intervention type: PROCEDURE
Intervention: thermal ablation
Description: thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
Study NCT06610604 — intervention group
Intervention type: PROCEDURE
Intervention: thyroidectomy
Description: surgical resection of thyroid nodules
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Engage in ABM + gratitude/savoring sessions
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Engage in inert attention task sessions
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive and respond to text messages to complete gratitude/savoring activity
Study NCT06682039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Message-Based Navigation Intervention
Description: Receive and respond to mood text messaging prompts
Study NCT06708572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
Study NCT06723197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan+amoxicillin
Description: Drug combinations for dual regimens：vonoprazan+amoxicillin
Study NCT06003036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: sham delivery of transcranial magnetic stimulation
Study NCT06003036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: accelerated intermittent theta burst stimulation
Study NCT06723197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan+amoxicillin
Description: Drug combinations for dual regimens：vonoprazan+amoxicillin
Study NCT06723197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of eradication regimen: 7-day
Description: Duration of eradication regimen: 7-day
Study NCT06723197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan+amoxicillin+tetracycline+bismuth
Description: Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
Study NCT06723197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of eradication regimen: 10-day
Description: Duration of eradication regimen: 10-day